CUAMC
RVNC

China Universal Asset Management Company’s Revance Therapeutics, Inc. RVNC Stock Holding History

China Universal Asset Management Company’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,243
Closed -$67.6K – 509
2024
Q4 		$67.6K Buy
22,243
+2,082
+10% +$9.07K 0.01% 430
2024
Q3 		$105K Buy
20,161
+7,890
+64% +$39.2K 0.01% 354
2024
Q2 		$31.5K Sell
12,271
-4,710
-28% -$16.1K ﹤0.01% 382
2024
Q1 		$83.5K Buy
16,981
+6,826
+67% +$40.4K 0.01% 387
2023
Q4 		$89.3K Buy
10,155
+7,905
+351% +$64.8K 0.02% 297
2023
Q3 		$25.8K Buy
2,250
+1,148
+104% +$22.1K 0.01% 284
2023
Q2 		$27.9K Sell
1,102
-20
-2% -$623 0.01% 238
2023
Q1 		$36.1K Buy
1,122
+286
+34% +$8.91K 0.01% 177
2022
Q4 		$15.4K Buy
836
+152
+22% +$3.48K 0.01% 193
2022
Q3 		$18K Buy
+684
New +$13.9K 0.01% 162

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's RVNC Position: Q1 2025 in Review

China Universal Asset Management Company sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 22,243 shares — an estimated $67.6K sold.

China Universal Asset Management Company first reported a position in RVNC in Q3 2022 and held it in 10 quarters. The position peaked at $105K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • China Universal Asset Management Company reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 22,243 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $67.6K.
  • China Universal Asset Management Company first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 10 quarters.
  • China Universal Asset Management Company's Revance Therapeutics, Inc. position peaked at $105K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on China Universal Asset Management Company's 13F filing for Q1 2025, filed 30 Apr 2025.